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Recent adulteration of milk products with melamine (ME) in several countries caused adverse
health effects and even deaths in infants. Earlier, in 2007, contamination of pet food with ME
and its related contaminants was associated with many clinical cases of canine and feline
nephrotoxicity, and in some cases mortality. ME is a triazine compound that is often detected
with other triazine analogs such as cyanuric acid. As is the custom in some livestock operations,
the contaminated pet food was mixed with feed intended for the swine and poultry industry.
This practice has raised several questions as to whether ME and its related triazines would
adversely affect the health of these food animals, and whether meat products derived from
swine and poultry could contain high-enough levels of these contaminants to warrant public
health concern. Data for this review article were obtained from recent research efforts in our
laboratory, peer-reviewed publications cited in PubMed, and information available at USDA, US
FDA, and WHO websites. The primary issues discussed are related to (1) the chemistry and
interactions between ME and its triazine analogs; (2) reported animal and human exposures
with possible pathways through which ME can enter the human food chain; (3) mammalian
toxicology; (4) comparative pharmacokinetics (PK) and modeling strategies used to predict
residue levels; and (5) emerging issues and management strategies.
Chemistry of melamine (ME) and related analogs
ME (2,4,6-triamino-s-triazine) is a chemical intermediate
used to manufacture amino resins and plastics in the United
States of America and elsewhere. The pKb (dissociation
constant for a weak base) of ME is nine, because of the
several amino groups that confer basic properties. ME is used
in making plastics and in other industrial processes,
while the related triazine compound sometimes detected
with ME, CA, is used in pool chlorination. CA, as well as
other chemically related triazines (Table 1), were also
by-products of plastics manufacturing. CA was also detected
in feed and food products during recent ME exposure
incidents. ME and its related triazines have been evaluated
as an alternative form of nitrogen fertilizer for plant growth.
Figure 1 depicts the chemical structure of these triazines
and demonstrates how they can change from one form
into another via hydrolysis and/or amination. This can
result in a mixture of ME and its related triazines, which
can cause renal toxicity, which will be described in more
detail later in this paper. These chemical reactions have
been well characterized in test tube experiments and they
can also occur as a result of incomplete reactions during
industrial production of ME. Evidence of bacterial degrada-
tion
1,2 of ME and other s-triazine herbicides suggests that
several of these reactions can occur in the gastrointestinal
tract and/or other biological fluids. Mixtures of ME and CA
can result in ME cyanurate crystal formation in vitro, in test
tubes and in the kidney (Figure 2), the target organ for
the ME-associated outbreaks of renal disease in pets and
human infants in recent years.
3,4 Prior to these events,
chemists had extensively reported on the complementary
hydrogen bonding between ME and CA in these crystals,
5
and that formation of such insoluble complex crystals is
pH-dependent.
6
Methods
Data for this review article were obtained from recent
research efforts in our laboratory, peer-reviewed publications
cited in PubMed (http://www.pubmed.gov), and information
available from websites of the OECD (http://www.inchem.
org/documents/sids/side/108781.pdf), the US FDA (http://www.
foodsafety.gov/-dms/melamine.html; wwwfda.gov/OHRMS/
DOCKET/98fr/07n-0208-ra00001.pdf), and the WHO (http://
www.who.int/foodsafety/fs_management/Melamine_3.pdf).
This is an Open Access article distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/2.5)
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Emerging Health Threats Journal 2010, 3:e5. doi: 10.3134/ehtj.10.005
& 2010 RE Baynes and JE Riviere; licensee Emerging Health Threats Journal.
www.eht-journal.orgLiterature searches produced relevant information available
in the public domain up until February 2009.
The PK analyses described in this review involved classical
PK and physiologically-based PK (PBPK) modeling techni-
ques, which are described in more detail in excellent PK
texts.
7–9 PK modeling is used in the risk assessment of toxic
substances to link internal dose concentrations at tissue
target sites with the exposed dose. In brief, classical PK
usually involves obtaining plasma or tissue concentrations of
a chemical over a selected time period and plotting the data
on the logarithmic y-axis to demonstrate a linear relation-
ship between plasma or tissue concentrations and time.
Classical PK analyses usually involve use of a software package
(for example, WinNonLin from Pharsight, Mountain View,
CA, USA) and apply several compartmental and non-compart-
mental modeling approaches. These analyses determine PK
parameters such as area under the curve (AUC), steady-state
volume of distribution (Vss), half-life (T1/2), mean residence
time (MRT), total body clearance (Cl), renal clearance (Clr),
absolute bioavailability (F), and absorption rate (Ka). Model
predictions versus observed plasma or tissue concentrations
can be shown on a graph to illustrate a model’s goodness of
fit. Statistical estimates of goodness of fit are often reported
as R
2, F test, Aikake’s Information Criterion and Schwarz’s
criterion.
PBPK models can also be predictive of a chemical’s
disposition, but they are based on physiological mecha-
nisms. This modeling process is, however, more data
intensive than classical PK analyses, and utilizes a series of
mass-balance equations. PBPK models link together tissue
and plasma compartments using parameters that are physio-
logical (for example, blood flow and tissue volumes),
physiochemical (for example, tissue:blood partition coeffi-
cients), and biochemical (protein binding, metabolism) in
nature. The mathematical modeling and simulation software
AcslXtreme (Aegis Technologies Group Inc., Huntsville,
AL, USA) can be used for model simulations, parameter
estimation, sensitivity analysis, and Monte Carlo analysis.
These PBPK models can be easily designed to incorporate
multiple routes of chemical administration to predict
internal dose metrics for human and animal exposure, and
also for interspecies extrapolation of model results in human
health risk assessment.
Human health risk assessments of chemical substances
usually involve gathering all the relevant toxicological data
from human epidemiological studies and animal studies. In
brief, the primary focus in this exercise is to define a
quantitative relationship between the dose of a chemical and
an adverse health effect, and then to determine the exposure
level at which the human population is least likely to be at
risk. Human exposure data are often not available, and
animal data need to be utilized in the assessment. With
adequate animal datasets, dose–response modeling can be
utilized; however, the risk assessor often resorts to a default
method known as the no observed adverse effect level
(NOAEL) approach, put in place to deal with the problem
of having limited dose–response data. As the name
indicates, the chemical dose that causes no adverse effect
is selected for further computation of the risk. This NOAEL
is then modified by several default uncertainty factors
Table 1 Physicochemical properties of melamine and its analogs
Properties Melamine Cyanuric acid Ammelide Ammeline
Molecular Weight 126.121 129.075 128.09 127.105
pKa 5.35 6.88–13.5 NA 9.0
pKb 9.0 NA NA NA
Solubility in water (g/l) 3.6 2.0 0.1 0.1
LogP  0.17 0.61 0.35  0.19
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Figure 1 Chemical structure of melamine and related contaminants, and chemical processes that lead to conversion of melamine to different triazine analogs.
Figure 2 Light micrograph illustrating characteristic melamine-containing
crystals (arrow) occluding the lumen of a renal tubule and necrosis of tubular
epithelial cells (arrowheads).
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differences (that is, to extrapolate the data from animals to
humans) and to account for intra-species differences. Based
on the above brief description of PBPK modeling, this
approach can be used as an effective tool to reduce much
of the uncertainty associated with NOAELs, and improve the
quality of risk assessment.
Exposure in livestock and humans
During the 2008 outbreak of ME nephrotoxicity in China,
infants were exposed to milk products contaminated with
ME at concentrations ranging from 0.1p.p.m. to a maximum
of 2563p.p.m. Dietary exposure was estimated to range from
8.6 to 23.4mg/kg b.w./day, based on median ME concentra-
tions linked to the adulteration of a specific infant formula.
3
More than 294,000 infants in China were exposed to these
contaminants, of which more than 50,000 were hospitalized
with nephrolithiasis and renal failure. At least six deaths
were documented in 2008. The age-specific incidence for
the illness was 85% for o2-year-olds, 17% for 2–3-year-olds,
and 0.8% for 43-year-olds.
10
In Hong Kong, approximately 3170 children were exposed
to low doses of ME in the range of 0.01–0.21mg/kg
b.w./day.
11 Of the approximately 3170 children (o12 years
old), one child had confirmed renal stones, seven were
suspected of having renal deposits, and 208 were positive for
hematuria. No renal obstruction or acute renal failure was
reported in the children exposed to these low doses.
Apart from the intentional adulteration of food products
in Asia, ME could potentially migrate from plastics. This is
estimated to result in a baseline exposure of 0.0019–13mg/kg
b.w./day for ME and 70mg/kg b.w./day for CA.
3 ME will
continue to be a public health concern because of its many
uses in the manufacturing and agrochemical sector. In late
2008, the US FDA detected ME (0.137p.p.m.) and CA
(0.247p.p.m.) in several samples of infant formula in the
USA. Only some of the above exposure assessments reported
exposure to mixtures of ME and CA, which is believed to be
more important from a public health perspective than from
the viewpoint of exposure to these individual chemicals.
There are no published data to indicate what threshold ratio
of ME-to-CA mixture can result in nephrotoxicity.
Swine feed can contain 5–10% of pet food scraps. However,
US FDA investigations during the recent ME contamination
incident determined that some swine herds were fed
50–100% of pet food scraps.
12 The concentration of the
triazines in these pet food scraps ranged from 9.4 to
1952p.p.m. for ME, while the highest values for CA,
ammelide, and ammeline were 2180, 10.8, and 43.3p.p.m.,
respectively. The final swine feed samples ranged from 30 to
120p.p.m. ME, with triazine analogs also being present at
lower concentrations. Assuming that the average food
consumption of an average market-weight pig of 91kg is
4% body weight, this can result in pigs being exposed to five
mg/kg b.w. of ME using the high-end concentration
(120p.p.m.) of confirmed swine feed samples, or 78mg/kg
b.w. of ME using the highest concentration in pet food scraps.
At the time of the US FDA investigation, the limit of
detection (LOD) for the analytical method was 50p.p.b.
(0.05p.p.m.) for ME only. Tissues from pigs believed to have
been exposed to contaminated pet food scraps rarely
contained ME levels above 50p.p.b. There were few details
regarding exact concentrations and duration of exposure,
which would allow for a reliable estimate of correlation
between ME exposure and tissue levels of ME.
Finally, it should be noted that this international incident
of ME contamination prompted many countries to establish
action limits for this contaminant and related analogs. For
example, a maximum ME limit of one p.p.m. was established
for infant formula and a maximum ME limit of 2.5p.p.m.
was established for milk products. Some countries have
established a limit of reporting (LOR) due to setting of
maximum limits as above instead of an analytical level of
determination such as the LOD or limit of quantitation
(LOQ). The reader should also be aware that, in most of the
surveys, the LOD or LOQ varies not only across food matrices
but also across laboratories and countries. The reporting of
positive ME samples should therefore be accompanied with
the LOD or LOQ of the analytical method used during the
survey. For example, the Chinese Center for Disease Control
and Prevention reported ME concentrations in infant
formula from Beijing and Gansu provinces ranging from
less than 0.05 to 4700p.p.m. The presence of positive
samples with levels less than 0.05p.p.m. suggests that the
LOD for the analytical method was less than 0.05p.p.m.
Health Canada reported ME concentrations ranging from
0.0043 to 0.346p.p.m., with an LOD of 0.004p.p.m. The
US FDA has also reported positive milk formula samples
at 0.137–0.206p.p.m., although these positive values were
below the LOQ of 0.25p.p.m. The above are just examples of
surveys in several countries where positive samples are often
below the LOQ and in most cases below the LOR.
Mammalian toxicology
Animal studies
Previous experimental studies determined that toxicity
to pure ME in mammals should be of minimal concern,
a finding supported by the large oral lethal dose (LD50)
of 3161mg/kg in rats.
13 Several other studies cited in this
OECD report describe a dose–response relationship between
ME and kidney stone formation in Fischer 344 rats given
63–1000mg/kg ME by oral feed for 13 weeks. Similar
dose–response relationships were also demonstrated in
B6C3F1 mice fed ME for 13 weeks, but at a higher dose
range than that tested in the Fischer 344 rats. The diuretic
effects of this chemical have been reported in rats and
dogs.
14
Male Fischer 344 rats exposed to extremely high doses of
ME in their diets for 36 to 103 weeks developed bladder
stones as well as transitional-cell carcinoma in statistically
significant proportions compared with controls.
15–17 These
studies consistently demonstrated that male rats, more so
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tumors. When B6C3F1 mice were exposed to higher
concentrations than the rats for the same exposure period,
only acute or chronic inflammation, epithelial hyperplasia,
and bladder stones (but no bladder tumors) were observed.
The carcinogenic effects observed in the rats were strongly
correlated with the presence of urinary bladder stones, and
there is no evidence of direct molecular interactions
attributed solely to ME. Genotoxicity studies also demon-
strated that ME is very unlikely to be a mutagen.
15,18 There
are, however, several reports suggesting that certain fatty
acids can modulate murine urinary proliferative lesions
induced by ME.
19,20
There is sufficient evidence to suggest that the mechanism
of renal toxicity in dogs and cats is associated with crystal-
lization of triazines in the kidney, followed by renal failure,
as observed with the adverse effects recently reported in pets
in the USA.
4,12,21,22 In all diagnostic reports about these
cases, ME alone does not appear to be toxic, but exposure
to ME and CA as a mixture, at doses ranging from 32 to
181mg/kg per chemical for about two days, caused charac-
teristic yellow-brown crystals in distal renal tubules and
collecting ducts, leading to nephrotoxicity.
23 These animals
all had markedly high concentrations of blood urea nitrogen
(BUN), creatinine, and isosthenuric urine. Often the urine
contained casts, leukocytes, erythrocytes, and yellow-brown
crystals. In three dogs that were exposed to pet food
suspected of contamination, infrared spectroscopy and
scanning electron microscopy with energy-dispersive X-ray
analysis were able to distinguish between calcium oxalate
crystals and ME-containing crystals.
24 In addition, histo-
chemical staining of kidney sections with Alizarin Red S was
used to demonstrate the presence of divalent cations
associated with calcium oxalate and calcium phosphate
crystals, while Oil Red O stains with ME-containing crystals
confirmed the presence of ME. The only domestic or
companion animal study that demonstrated similar nephro-
toxicity after exposure to apparently a ME-only gavage
involved sheep exposed to high doses of approximately
200mg/kg for several days.
25 Although published some time
ago, the observations from this study suggest that rumen
metabolism may play a role in the conversion of ME to
analogs that result in crystal formation and subsequent
nephrotoxicity in the sheep.
Recent studies conducted by the US FDA
26 have reported
that no microscopic crystals were observed in the kidney
when fish or swine were exposed to either ME or CA, at
400mg/kg of either contaminant for three days with a one-
day withdrawal. However, when these two contaminants
were fed to either species as a mixture for the same time
period at a high dose of 400mg/kg for each contaminant,
crystals were observed in the kidney. Interestingly, ME–CA
crystals were also detected in the intestines of the pigs that
were exposed to a 1:1 ratio of MEþCA. Furthermore, tissue
levels of ME or CA were greater when given as individual
chemicals, but these levels were significantly lower when the
chemicals were given as a mixture, suggesting that crystal-
lization in the intestines may have limited bioavailability.
However, bioavailability was not assessed, and neither were
urine or blood levels of either triazine. Dose composition
could not be predicted from crystal composition, which had
a consistently higher ME/CA ratio than the equimolar (1:1)
dose used in this study.
Several biomarkers of renal toxicity (BUN, creatinine,
creatinine clearance) are responsive to exposure to ME–CA
mixtures.
27 This study
27 demonstrated significant changes in
BUN, serum creatinine, and creatinine clearance when rats
were exposed to single-dose mixtures (1:1), or three doses of
mixtures (1:1 or 10:1); it also demonstrated a potential dose–
response relationship across dose and ME/CA ratios. This
study was also unable to demonstrate the in vitro cytotoxicity
of individual triazines in canine kidney cells (MDCK) and
feline kidney cells. Furthermore, the study did not evaluate
the cytotoxicity of ME–CA mixtures in these in vitro systems.
Human studies
Prior to the ME-poisoning cases seen in China in 2008,
there was no evidence demonstrating the adverse
effects of exposure to a mixture of both contaminants in
humansFeven though crystal obstructive nephropathies
leading to acute renal failure are well documented in
humans following exposure to several drugs such as some
sulfonamides (for example, sulfadiazine), acyclovir, or
methotrexate.
28,29 The mechanisms of crystal-induced in-
flammation in diverse cell types caused by various crystals
such as calcium oxalate, calcium phosphate, and urate have
also been well characterized.
30 However, the mechanisms
associated with the adverse effects of ME cyanurate crystals
on renal tubular cells have not been investigated. Cases of
possibly similar pathogenesis, where nephroliths form to
cause subsequent renal toxicity, have been associated with
human exposure to triamterene and xemilofiban/orbofiban.
These are chemicals with nitrogen-ring-based structures
whose toxicity is highly variable and is dependent on
concentration as well as urine variables that promote
precipitation in the tubular fluid.
31 Because of the similarity
of clinical syndromes between these drugs and ME, one
could hypothesize the plausibility of a similar mechanism.
More importantly, other nephrotoxins that do not share the
same chemical structure as ME or drugs with nitrogen-ring
base structures result in different signs of clinical toxicology.
Several recent publications have attempted to correlate the
known exposure levels of ME in powdered milk,
32 and ME
levels in urine,
33 with urolithiasis in infants in China. The
study by Guan et al.
32 demonstrated that infants exposed to
the high-ME formula (4500p.p.m. ME) were seven times as
likely to have stones as those exposed to ME-free formula,
and preterm infants were 4.5 times as likely to have stones as
full-term infants. Urinalysis did not appear to be an adequate
method of screening for ME-associated urinary stones.
Biomarkers of early renal disease suggest that ME-related
stone formation appeared to be associated more with
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study by Lam et al.
33 determined that urine ME levels could
be a biomarker of residual ME load in the body, and found a
strong correlation between renal stone size and urinary ME
levels. However, there was no such correlation for CA levels
in urine.
Pharmacokinetics
The most complete PK modeling study was performed in
male Fischer 344 rats exposed to a single oral dose of 0.38mg
(1.3mg/kg b.w.) of radiolabeled (
14C) ME.
34 In a one-week
feeding study in male Wistar rats, ME was not absorbed in
the stomach, but exponential absorption occurred in the
small intestine.
35 The former study demonstrated that
plasma half-life was about three hours, more than 90% of
the oral dose was eliminated in the urine within 24h, and
more ME was recovered in the kidney and bladder than in
other tissues. These PK findings provide some support for the
toxicity reported in rats, which is thought to have led to the
adverse effects observed in pets exposed to ME-contaminated
pet food and infants exposed to contaminated milk.
Our laboratory was the first to describe the PK of ME given
as a single intravenous (IV) dose to pigs in order to obtain
basic PK parameters.
36 A one-compartment, first-order
kinetic, IV bolus model was found to be the best model for
the data (Figure 3), and first-order elimination was assumed
based on previously reported rodent data.
34 The estimated
half-life, clearance, volume of distribution at steady state,
and AUCs are listed in Table 2. Individual parameter values
were calculated from each pig. The volume of distribution of
ME in pigs (0.6170.04l/kg) was close to that of total body
water, suggesting that the distribution of this chemical for
the most part may be limited to the extracellular fluid
compartment. The limited distribution in the pig is con-
sistent with data from the earlier rat study,
34 which
demonstrated that tissue distribution may be limited to the
total body water, with ME possibly binding to the kidney,
which is the organ primarily responsible for its clearance.
This is a safe assumption for the pig, as ME is not
metabolized by the liver in other animals.
37
ME appears to be cleared rapidly (T1/2¼4.0770.39h) and
monoexponentially in the pig, with a half-life that is
approximately 1.5 times longer than that seen in the rat
(T1/2¼2.71h). This is, in turn, primarily due to an almost
five-fold greater renal clearance in the rat than in the pig, in
spite of the apparent volume of distribution in the rat study
(1.8l/kg) being three times greater than that in the pig
(0.61l/kg). Clearance mechanisms for ME and its analogs
have not been characterized in various animal species;
however, based on its physicochemical properties as a small
polar molecule, and its clearance values (0.11l/h/kg or
27ml/min), ME can be assumed to be primarily cleared
by renal filtration in the pig. The fact that the glomerular
filtration rate (GFR) of our weanling pigs (15kg) is
approximately 31–42ml/min
38 supports this preliminary
assessment.
Pigs’ blood would be cleared of about 99% of the ME dose
within seven half-lives or 28h after exposure, and this blood
concentration should be below the safe level of 50ng/ml
(50p.p.b.) proposed by the United States Food Safety
Inspection Service (US FSIS)
39 for a dose of six mg/kg. This
proposed safe level is based on the LOQ for the assays
developed by US FSIS. In the likely scenario that pigs were
accidentally exposed to a large oral dose that resulted in a
maximum plasma concentration of 10mg/ml, as in our IV
study,
36 based on extrapolation of our PK model, it would
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Figure 3 Plasma concentration–time profiles of melamine in swine. The solid line indicates plasma concentrations generated from the one-compartment model
and observed data points. Source: Baynes et al.
36
Table 2 Pharmacokinetic parameters for melamine in pigs following IV dose
of 6mg/kg melamine
T1/2 (h) Cl (l/h/kg) Vss (l/kg) AUC (hmg/ml) Kel (1/h) MRT (h)
Mean 4.07 0.11 0.61 59.26 0.18 5.87
Abbreviations: AUC, area under the curve extrapolated to infinity;
Cl, clearance; Kel, elimination rate constant; MRT, mean residence time;
T1/2, half-life; Vss, volume of distribution.
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proposed safe concentration. The earlier rat studies
34
provided an incomplete dataset to estimate depletion of
the chemical from the body, because the selection of
inadequate sample times did not allow for appropriate
estimation of the ME half-life in the rat kidney. Further-
more, all these pig and rat studies used exposures to
pure ME; so the effects of concurrent triazine exposure
(MEþCA) on ME disposition and tissue withdrawal time are
not known.
Although not thoroughly investigated, the available
evidence suggests that ME does not undergo significant
hepatic metabolism and should, for the most part, be readily
cleared solely by the kidney. However, biliary excretion
cannot be ruled out and requires further investigation. ME
can be broken down by hydrolytic enzymes and bacteria to
CA, ammelide, and ammeline.
40 There is reason to believe
that digestive enzymes can have a similar effect on ME, with
the resulting metabolites appearing in the urine and feces.
At low doses of five mg/kg, CA appears to be readily
absorbed via the gastrointestinal tract of rats and largely
eliminated in the kidney without being metabolized, result-
ing in a half life of 0.5–1.0h.
41 But at a higher dose of
500mg/kg, the chemical is incompletely absorbed and
eliminated mostly in the feces, with a half-life of 2.5h. CA
does not appear to bioaccumulate in rats given the lower
dose for 14 days. Similar findings were observed in dogs
given the same doses, except that elimination half-lives were
estimated at 1.5–2.0h with no metabolism.
As clearance of ME and its analogs is dependent on
elimination via the kidney, there is the possibility that ME
cyanurate crystal formation and related renal pathologies in
the renal tubules could reduce the renal clearance of ME and
its analogs. Numerous clinical PK studies have demonstrated
the influence of compromised renal clearance on plasma and
tissue concentrations of various drug classes following renal
disease.
7,8 Ethylene glycol-induced nephrotoxicity is well
documented in the literature, and more recent work
described increased sensitivity to oxalate crystal formation
in some rats, leading to degeneration of the renal tubule
epithelium.
42,43 Based on the data from this study, it appears
possible that ME cyanurate crystal formation in the renal
tubule can reduce the kidney’s capacity to excrete these
triazine contaminants (oxalic acid or ME/CA), and this
further exacerbates toxicity. However, a more recent study
42
demonstrated no statistically significant differences in renal
clearance between treated animals and controls, and renal
clearance of oxalic acid appears to be unaffected in humans
with urolithiasis, glomerulonephritis, or polycystic kidney
disease.
44 ME cyanurate crystals in swine or humans may be
different: unlike normal crystals in dogs, which may cause
chronic obstruction, ME cyanurate crystals were acutely
lethal and caused acute renal failure. As a further note on
how oxalic acid is cleared by the kidney across different
species,
14C-oxalate-to-inulin renal clearance ratios in
healthy rats were lower than one, indicating that a fraction
of the filtered oxalate was reabsorbed,
42 contrary to what
happens in humans, sheep, and dogs.
45,46
Our laboratory has also modeled ME disposition in rats
following an oral bolus exposure.
47 This four-tissue compart-
ment PBPK model (Figure 4) compared somewhat favorably,
based on R
2 values (R
2¼0.59–0.76), with limited tissue data
from the rat study.
34 Similar strategies were used to model
ME disposition in pigs following IV bolus exposure with
better predictions (R
2¼0.89) for plasma data (Figure 5). No
tissue samples were analyzed in this preliminary IV study in
pigs. However, the PBPK model was used to predict a tissue-
withdrawal time of 21h for a 5.12mg/kg single oral bolus,
although we have no in vivo pig studies to validate these
estimates. Further studies are also needed to test our model
assumptions on parameters such as species differences in
tissue:plasma partitioning, rates of intestinal absorption, and
renal clearance mechanisms such as differences in GFR, dose
linearity, and tissue dosimetry.
The inherent value of a PBPK modeling method is that it
incorporates species-specific physiological and biochemical
processes that can be evaluated to determine their influence
on tissue disposition of a chemical. This approach is not
driven by tissue time–concentration curves, which is typical
of the classical compartmental PK or data-based PK model-
ing, which assume a specific model structure and derive
model parameters by curve fitting. This classical approach
assumes that absorption, distribution, metabolism, and
excretion processes are first order, but does not always take
into account potential saturation clearance limitations for
some chemicals, or that blood flow can limit clearance.
In PBPK modeling, once a conceptual and realistic model
has been defined, physiological and biochemical data
parameters such as blood flow, tissue volumes, metabolic
constants, and blood:tissue partitioning values can be
obtained from the literature and/or from separate in vitro
laboratory experiments. Once the model has been devel-
oped, one can determine the influence of variability and
uncertainty of physiological parameters on the model out-
put. For example, swine body weight and blood flow vary
within a population; therefore, a method known as Monte
Carlo technique can be used to understand the variability
of the response or kinetic behavior of these triazine
compounds.
Human health risk assessment
The risk assessment of ME is complicated by the fact that
differential toxicity has been reported across various animal
species. It is reasonable to assume that species-specific
toxicokinetics and renal toxicology may contribute to
reported species differences. Many human and animal
studies do not report the purity of the ME exposure and/or
the purity of the urine samples to ascertain whether CA or
other triazines were present in these matrices. Current
human health risk assessments are based on a rat study,
which has derived a NOAEL of 63mg/kg b.w./day based on
stone formation in rats.
10 An uncertainty factor of 100 is
Risks associated with melamine Emerging Health Threats Journal
RE Baynes and JE Riviere 2010, 3:e5
www.eht-journal.org page 6/10used for inter-species and intra-species extrapolations, and
an additional safety factor of 10 for combined exposures to
ME and CA. We note that it is mixtures of ME and CA that
have been implicated in the recent human and pet
nephrotoxicity incidents. From these calculations, the total
daily intake was determined to be 0.063mg/kg b.w./day, or a
daily intake of 3.78mg/person/day. A safe level or tolerance
level in food was calculated at 2.5p.p.m., assuming a food
consumption rate of 1.5kg/day. This calculation was also
modified for infants weighing three kg and consuming
0.15kg of food; that is, the new safety level for ME would be
1.26 or 1.00p.p.m., to provide an additional margin of
safety.
10 In other words, if 100% of an infant’s diet was
contaminated at a level of 1.26p.p.m. of ME (0.189mg ME
per 0.15kg food), the daily intake would equal 0.063mg/kg
b.w./day, suggesting that the 1.00p.p.m. safety level provides
an additional margin of safety. These are currently set as
interim safety levels and will probably be revised as we gain a
better understanding of the toxicokinetics and toxicology of
these chemical mixtures in sensitive subpopulations.
Emerging issues and management of
contamination
There are now significant human epidemiological
32,33 and
animal experimental data
26,27 that humans or animals
exposed to mixtures of ME and CA in their diets are very
likely to develop crystal nephropathy that can result in acute
renal failure and possibly death. The human studies did not
report whether infants were exposed to mixtures of ME and
CA. However, the animal experimental studies strongly
suggest that the affected infants were most likely exposed
to mixtures of both triazines in the milk formula. It is very
likely that adulterants such as ME and related triazines will
be used as a cheap nitrogen source in the face of limited
protein/feed supply. Future protein substitutes in human
food and milk may contain these triazines either individu-
ally or as a mixture. Furthermore, the widespread use of
related triazines in numerous applications (for example, as
herbicides) suggests the potential for significant occupa-
tional exposures and environmental exposure, perhaps
through contamination of water sources. This highlights
the need to better understand the disposition of and
toxicological interactions between these triazines in animals
as well as humans.
Management of any future outbreaks linked to ME
contamination of animal feed and human food will require
access to state-of-the-art screening and confirmatory analy-
tical methods to identify and quantify the presence of ME
and its related triazines, both in food items and in biological
matrices. The literature
48–50 describes numerous ELISA, LC,
and GC techniques that have been successfully used to
analyze these triazines in feed, blood, urine, and tissues.
X-ray diffraction and Fourier transform IR spectra of crystals
formed in these matrices, together with mass spectrometry,
have been used and can be used for identifying crystals and
confirming their chemical composition in pets and human
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Figure 4 (a) Schematic illustration of the physiologically based pharmacokinetic model of melamine. This model was used in both rat and porcine species.
The arrows represent mass transfer of melamine via blood flow. (b) Schematic representation of the chronic oral dosing regimen. Kst and Ka represent the rate of
gastric emptying and rate of absorption, respectively. Source: Buur et al.
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management, identification of reliable biomarkers of ex-
posure and toxicity could provide improved diagnostic tools
during the early stages of an outbreak. To date, many of the
available clinical pathology parameters of urolithiasis appear
to be of limited diagnostic value in screening patients for
ME-induced urolithiasis, as demonstrated in the recent study
by Guan et al.
32
An understanding of how these triazines are cleared from
circulation in livestock can be used in managing future
outbreaks and preventing adulterated food of animal origin
from entering the human diet. In addition to improved
chemical analytical methods for animal feed and human
food analysis, PBPK modeling can be used in conjunction
with residue data from tested livestock to estimate when
meat and milk products are safe for human consumption.
There are, however, significant gaps in data with regard to
(1) PK and tissue disposition following oral exposure to
ME–CA mixtures, (2) the physiological and physicochemical
factors that can influence the PK of simultaneous exposure
to these mixtures, (3) the ratios and doses of ME–CA
mixtures that can cause nephrotoxicity, and (4) the dose–
response relationship between exposure to the mixture and
renal adverse effects.
Current risk assessments are based on exposures to ME
alone, and not to any mixture of ME and its related triazines.
There has been an increased awareness of the importance of
chemical mixtures in risk assessment and most of these
studies have demonstrated that single chemical toxicity data
are not predictive of the toxicity seen after exposure to the
same chemicals in complex mixtures. There are numerous
possible interactions between the chemicals based on
alterations in systemic disposition, biotransformation, or
toxicodynamic interactions at the membrane, cellular, or
receptor level. These interactions may be additive, synergis-
tic, or antagonistic. Based on preliminary data presented in
this review, the interaction between ME and CA may not be
deemed synergistic in the classical toxicology sense,
although exposure to any one of these triazines is less likely
to cause adverse renal effects compared with a mixture of
both triazines. There is clearly a need to increase the capacity
to assess the risk to animal and human health following
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Figure 5 Validation data for porcine melamine PBPK model against porcine plasma data. (a) Model simulation (solid line) and observed data (squares) and
(b) regression analysis between model simulation and observed data. Source: Buur et al.
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known interacting chemicals such as these triazines needs to
be handled differently from that which involves single
chemicals.
Conclusions
Recent ME contamination incidents crossed international
boundaries and involved contamination of not only milk
products but also other food items. This review highlights
human and livestock exposure to this contaminant and/or
its analogs, and the adverse health effects seen in exposed
infants. Performing an adequate risk assessment of this
contaminant and its analogs is limited by insufficient
human and animal dose–response toxicology data, among
many data gaps. Although ME is not metabolized by the liver
and does not appear to accumulate in the body, as it is
rapidly eliminated by the kidney, there is little or no
mechanistic information to guide risk assessment when a
mixture of ME and CA or other analogs are simultaneously
cleared by the kidney. Further work is needed to assess the
carry-over ratios of ME and related analogs from feed, animal
products, oral bioavailability, and renal clearance in order to
better determine tissue dosimetry in the human body if a
similar food contamination incident was to threaten human
health again.
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